In connection with the Amendment, Peter Traber, Selecta Biosciences, Inc.?s Chief Medical Officer, has agreed to serve as a consultant to Sobi and move to part-time status as the Company?s Chief Medical Officer, each effective as of November 6, 2023. On October 31, 2023, the Company and Dr. Traber entered into an amended and restated employment agreement (the ?Amended Employment Agreement?), dated as of October 31, 2023, pursuant to which Dr. Traber?s working time and efforts to the business and affairs of the Company were reduced by 50%, his annual base salary was reduced to $250,000 and his target bonus for 2023 was adjusted such that it will be calculated based upon (i) his aggregate base salary through November 5, 2023 under his prior employment agreement plus (ii) his aggregate base salary from November 6 through the remainder of 2023 under the Amended Employment Agreement.